Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Insulet
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
45.0%
+6.0% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:DominantThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
Medtronic
Competitor Displacement Rate
20.0%
Competitors are displacing Insulet in 20.0% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Medtronic's established market share and diverse insulin delivery systems are gaining traction. Insulet's strength lies in its tubeless approach, which needs more algorithmic promotion.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[beyondtype1.org][diabetic.org]⚠️ Identified Vulnerability:Device Innovation
Primary Threat Identified:Medtronic
Target Persona:Type 1 Diabetes Patients
🚨 Threat Velocity:7/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)